Suboptimal Peak Inspiratory Flow and Critical Inhalation Errors are Associated with Higher COPD-Related Healthcare Costs

References

• Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397–412. doi:10.1183/09031936.06.00025805
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2020. Available from: www.goldcopd.org. Accessed September 13, 2022.
   Google Scholar
• Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. Int J COPD. 2020;15:439–460. doi:10.2147/COPD.S234942
   Google Scholar
• Bosnic-Anticevich SZ. Inhaler device handling: have we really started to address the problem? Eur Respir J. 2017;49(2):1700120. doi:10.1183/13993003.00120-2017
   PubMed Web of Science ®Google Scholar
• Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med. 2009;122(4):348–355. doi:10.1016/J.AMJMED.2008.09.042
   PubMed Web of Science ®Google Scholar
• Ghosh S, Pleasants RA, Ohar JA, Donohue JF, Drummond MB. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD. Int J COPD. 2019;14:585–595. doi:10.2147/COPD.S195438
   Google Scholar
• van der Palen J. Peak inspiratory flow through Diskus and Turbuhaler, measured by means of a peak inspiratory flow meter (In-Check DIAL ®). Respir Med. 2003;97(3):285–289. doi:10.1053/rmed.2003.1289
   PubMed Web of Science ®Google Scholar
• Clark AR, Weers JG, Dhand R. The confusing world of dry powder inhalers: it is all about inspiratory pressures, not inspiratory flow rates. J Aerosol Med Pulm Drug Deliv. 2020;33(1):1–11. doi:10.1089/jamp.2019.1556
   PubMed Web of Science ®Google Scholar
• Virchow JC, Weuthen T, Harmer QJ, Jones S. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study. Expert Opin Drug Deliv. 2014;11(12):1849–1857. doi:10.1517/17425247.2014.949236
   PubMed Web of Science ®Google Scholar
• Newhouse MT, Nantel NP, Chambers CB, Pratt B, Parry-Billings M. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. Chest. 1999;115(4):952–956. doi:10.1378/chest.115.4.952
   PubMed Web of Science ®Google Scholar
• Kocks WH, Wouters J, Bosnic-Anticevich H, et al. Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers. Npj Prim Care Respir Med. 2022;32(1):18. doi:10.1038/s41533-022-00282-y
   PubMed Web of Science ®Google Scholar
• Leving MT, Kocks J, Bosnic-Anticevich S, Dekhuijzen R, Usmani OS. Relationship between peak inspiratory flow and patient and disease characteristics in individuals with COPD:A systematic scoping review. Biomedicines. 2022;10(2):458. doi:10.3390/BIOMEDICINES10020458
   Web of Science ®Google Scholar
• Klijn SL, Hiligsmann M, Evers SMAA, et al. Effectiveness and success factors of educational inhaler technique interventions in asthma & COPD patients: a systematic review. Npj Prim Care Resp Med. 2017;27(1). doi:10.1038/s41533-017-0022-1
   Web of Science ®Google Scholar
• Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19(1):1–20. doi:10.1186/S12931-017-0710-Y/TABLES/2
   Web of Science ®Google Scholar
• Torvinen S, Nicolai J, Pulimeno S, et al. The budget impact of Duoresp® Spiromax® compared with commonly prescribed dry powder inhalers for the management of asthma and chronic obstructive pulmonary disease in Italy: estimated impact of inhalation technique. Value Health. 2015;18(7):A496. doi:10.1016/j.jval.2015.09.1391
   Web of Science ®Google Scholar
• Lewis A, Blackney M, Torvinen S, et al. The budget impact of Duoresp® Spiromax® (budesonide + formoterol fumarate dihydrate) compared with Symbicort® Turbohaler® for the management of asthma and chronic obstructive pulmonary disease in the United Kingdom: impact on health care costs and inhalation technique. Value Health. 2014;17(7). doi:10.1016/j.jval.2014.08.2027
   Web of Science ®Google Scholar
• Lewis A, Blackney M, Torvinen S, et al. The potential societal cost benefits of improved inhalation technique with Duoresp® Spiromax® (budesonide + formoterol fumarate dihydrate) compared with Symbicort® Turbuhaler® for the management of asthma and chronic obstructive pulmonary disease in Sweden. Value Health. 2014;17(7). doi:10.1016/j.jval.2014.08.2070
   Web of Science ®Google Scholar
• Lewis A, Blackney M, Garcia Bujalance L, Sánchez-de la Rosa R, Torvinen S, Plich A. The potential for improved inhalation technique with Duoresp® Spiromax® (Budesonide + formoterol fumarate dihydrate) compared with commonly prescribed dry powder inhalers for the management of asthma and chronic obstructive pulmonary disease in Spain: estimated impact on number and cost of unscheduled healthcare events. Value Health. 2015;18(7). doi:10.1016/j.jval.2015.09.638
   Web of Science ®Google Scholar
• Roggeri A, Micheletto C, Roggeri DP. Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues. Int J Chron Obstruct Pulmon Dis. 2016;11(1):597. doi:10.2147/COPD.S103335
   Web of Science ®Google Scholar
• Bijos P, Kaczynski J, Torvinen S, et al. Clinical and economic burden of asthma and chronic obstructive pulmonary disease (COPD) in Poland: estimated impact of poor inhalation technique with inhaled corticosteroid and long-acting beta agonist fixed-dose combinations. Value Health. 2015;18(7):A499. doi:10.1016/J.JVAL.2015.09.1408
   Web of Science ®Google Scholar
• Lewis A, Blackney M, Torvinen S, Plich A. Clinical and economic burden of asthma and chronic obstructive pulmonary disease in the UK: impact of critical inhaler errors with inhaled corticosteroid + long-acting beta agonist fixed-dose combinations. Value Health. 2014;17(3):A174. doi:10.1016/J.JVAL.2014.03.1016
   Web of Science ®Google Scholar
• Cramer JA, Bradley-Kennedy C, Scalera A, Cramer J, Bradley-Kennedy C, Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J. 2007;14(1):25–29. doi:10.1155/2007/161652
   PubMed Web of Science ®Google Scholar
• Price D, Keininger DL, Viswanad B, Gasser M, Walda S, Gutzwiller FS. Factors associated with appropriate inhaler use in patients with COPD – lessons from the REAL survey. Int J Chron Obstruct Pulmon Dis. 2018;13:695. doi:10.2147/COPD.S149404
   PubMed Web of Science ®Google Scholar
• Ramsey SD. Suboptimal medical therapy in COPD: exploring the causes and consequences. Chest. 2000;117(2):33S–37S. doi:10.1378/CHEST.117.2_SUPPL.33S
   Web of Science ®Google Scholar
• Rand CS. Patient adherence with COPD therapy. Eur Respir Rev. 2005;14(96):97–101. doi:10.1183/09059180.05.00009604
   Google Scholar
• Blackstock FC, Wallack RZ, Nici L, Lareau SC. Why don’t our patients with chronic obstructive pulmonary disease listen to us? The enigma of nonadherence. Ann Am Thorac Soc. 2016;13(3):317–323. doi:10.1513/ANNALSATS.201509-600PS/SUPPL_FILE/DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(10):1333–1343. doi:10.1164/rccm.201604-0733OC
   PubMed Web of Science ®Google Scholar
• Toy EL, Beaulieu NU, Mchale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435–441. doi:10.1016/j.rmed.2010.09.006
   PubMed Web of Science ®Google Scholar
• Simoni-Wastila L, Wei YJ, Qian J, et al. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a medicare population. Am J Geriatr Pharmacother. 2012;10(3):201–210. doi:10.1016/J.AMJOPHARM.2012.04.002
   PubMedGoogle Scholar
• van Boven JFM, Chavannes NH, van der Molen T, Rutten-Van Mölken MPMH, Postma MJ, Vegter S. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med. 2014;108(1):103–113. doi:10.1016/J.RMED.2013.08.044
   PubMed Web of Science ®Google Scholar
• Leving M, Wouters H, de la Hoz A, et al. Impact of PIF, inhalation technique and medication adherence on health status and exacerbations in COPD: protocol of a real-world observational study (PIFotal COPD Study). Pulm Ther. 2021;7(2):591–606. doi:10.1007/s41030-021-00172-7
   Google Scholar
• Sanders MJ. Guiding inspiratory flow: development of the in-check DIAL G16, a tool for improving inhaler technique. Pulm Med. 2017;2017:1–7. doi:10.1155/2017/1495867
   Web of Science ®Google Scholar
• Plaza V, Fernández-Rodríguez C, Melero C, et al. Validation of the “Test of the Adherence to Inhalers” (TAI) for asthma and COPD patients. J Aerosol Med Pulm Drug Deliv. 2016;29(2):142–152. doi:10.1089/JAMP.2015.1212/ASSET/IMAGES/LARGE/FIGURE3.JPEG
   PubMed Web of Science ®Google Scholar
• Duarte AG, Tung L, Zhang W, Hsu ES, Kuo YF, Sharma G. Spirometry measurement of peak inspiratory flow identifies suboptimal use of dry powder inhalers in ambulatory patients with COPD. COPD. 2019;6(3):246. doi:10.15326/JCOPDF.6.3.2018.0163
   Google Scholar
• Kawamatawong T, Khiawwan S, Pornsuriyasak P. Peak inspiratory flow rate measurement by using In-Check DIAL for the different inhaler devices in elderly with obstructive airway diseases. J Asthma Allergy. 2017;10:17. doi:10.2147/JAA.S127580
   PubMed Web of Science ®Google Scholar
• Al-Showair RAM, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101(11):2395–2401. doi:10.1016/J.RMED.2007.06.008
   PubMed Web of Science ®Google Scholar
• Loh CH, Peters SP, Lovings TM, Ohar JA. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann Am Thorac Soc. 2017;14(8):1305–1311. doi:10.1513/AnnalsATS.201611-903OC
   PubMed Web of Science ®Google Scholar
• Peché R, Attar‐zadeh D, Scullion J, Kocks J. Matching the inhaler to the patient in COPD. J Clin Med. 2021;10(23):5683. doi:10.3390/JCM10235683
   PubMed Web of Science ®Google Scholar
• Harb HS, Laz NI, Rabea H, Abdelrahim MEA. Prevalence and predictors of suboptimal peak inspiratory flow rate in COPD patients. Eur J Pharmaceut Sci. 2020;147:105298. doi:10.1016/J.EJPS.2020.105298
   PubMed Web of Science ®Google Scholar
• Wallace AE, Shinde MU, Willey VJ, et al. Health care resource utilization and exacerbation rates in patients with COPD Stratified by disease severity in a commercially insured population. J Manag Care Spec Pharm. 2019;25(2):205–217. doi:10.18553/JMCP.2019.25.2.205
   Web of Science ®Google Scholar
• Fletcher MJ, Upton J, Taylor-Fishwick J, et al. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health. 2011;11(1):1–13. doi:10.1186/1471-2458-11-612
   Web of Science ®Google Scholar